{"content":"<li class=\"n-box-item date-title\" data-end=\"1552708799\" data-start=\"1552622400\" data-txt=\"Monday, December 23, 2019\">Friday, March 15, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3443440\" data-ts=\"1552686393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443440-clne-cara-syna-and-neos-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CLNE, CARA, SYNA and NEOS among notable after hour movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a> <font color=\"green\">+5.8%</font>. <a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a> <font color=\"green\">+4.1%</font>. <a href='https://seekingalpha.com/symbol/VICR' title='Vicor Corporation'>VICR</a> <font color=\"green\">+3.5%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics, Inc.'>CARA</a> <font color=\"green\">+3.3%</font>. <a href='https://seekingalpha.com/symbol/EQM' title='EQM Midstream Partners, LP'>EQM</a> <font color=\"green\">+3.2%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics, Inc.'>NEOS</a> <font color=\"red\">-6.7%</font>. <a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a> <font color=\"red\">-6.1%</font>. <a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a> <font color=\"red\">-5%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color=\"red\">-3.9%</font>. <a href='https://seekingalpha.com/symbol/HARP' title='Harpoon Therapeutics, Inc.'>HARP</a> <font color=\"red\">-2.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443440\" data-linked=\"CLNE, CARA, SYNA and NEOS among notable after hour movers\" data-tweet=\"$LPTX $CLNE $VICR - CLNE, CARA, SYNA and NEOS among notable after hour movers https://seekingalpha.com/news/3443440-clne-cara-syna-and-neos-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443440-clne-cara-syna-and-neos-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443424\" data-ts=\"1552683265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443424-synapticsminus-7-on-ceo-departure-outlook-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics -7% on CEO departure, outlook cut</a></h4><ul><li>Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) <a href=\"https://seekingalpha.com/pr/17446075-synaptics-announces-leadership-transition\" target=\"_blank\">announces</a> that CEO Richard Bergman has departed, effective immediately. The company says the departure wasn't the result of a disagreement regarding SYNA's operations, policies, or practices.</li><li>The board has created an exec leadership committee to assist with the transition and director Nelson Chan has been elected as Executive Chairman.</li><li>SYNA says its Q3 will now come in at the lower end of the prior guidance that put revenue from $340M to $380M and EPS from $0.70 to $1.</li><li>Synaptics <font color=\"red\">plunges 7%</font> after hours to $40.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443424\" data-linked=\"Synaptics -7% on CEO departure, outlook cut\" data-tweet=\"$SYNA - Synaptics -7% on CEO departure, outlook cut https://seekingalpha.com/news/3443424-synapticsminus-7-on-ceo-departure-outlook-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3443424-synapticsminus-7-on-ceo-departure-outlook-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443386\" data-ts=\"1552680548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLBS\" target=\"_blank\">GLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443386-globus-maritime-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globus Maritime reports Q4 results</a></h4><ul><li>Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>): Q4 GAAP EPS of -$0.42.</li><li>Revenue of $4.36M (+10.4% Y/Y)</li><li>Shares <font color=\"green\">+1.94%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17446024-globus-maritime-limited-reports-financial-results-quarter-year-ended-december-31-2018\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443386\" data-linked=\"Globus Maritime reports Q4 results\" data-tweet=\"$GLBS - Globus Maritime reports Q4 results https://seekingalpha.com/news/3443386-globus-maritime-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443386-globus-maritime-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443365\" data-ts=\"1552677770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGTA\" target=\"_blank\">MGTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443365-raymond-james-sees-73-upside-in-magenta-therapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James sees 73% upside in Magenta Therapeutics</a></h4><ul><li>Raymond James is bullish (Outperform/$22) on Magenta Therapeutics (<a href='https://seekingalpha.com/symbol/MGTA' title='Magenta Therapeutics, Inc.'>MGTA</a> <font color=\"green\">+24.1%</font>) citing the value propositions of its MGTA-456, MGTA-145 and C200 programs, adding that Phase 2-stage MGTA-456 could generate $50M in U.S. sales in 2027.</li><li>Shares are up on almost triple normal volume in response to <a href=\"https://seekingalpha.com/news/3436624-magenta-7-percent-cell-therapy-data\" target=\"_blank\">mid-stage data</a> on MGTA-456 that showed a high level of engraftment of the stem cells with minimal side effects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443365\" data-linked=\"Raymond James sees 73% upside in Magenta Therapeutics\" data-tweet=\"$MGTA - Raymond James sees 73% upside in Magenta Therapeutics https://seekingalpha.com/news/3443365-raymond-james-sees-73-upside-in-magenta-therapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/3443365-raymond-james-sees-73-upside-in-magenta-therapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443362\" data-ts=\"1552676958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443362-bmo-bullish-on-gilead-sees-20-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMO bullish on Gilead, sees 20% upside</a></h4><ul><li>BMO's Matthew Luchini (Outperform/$78) says Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+1.1%</font>) is a buy citing its HIV franchise that \"should be dominant for at least the next several years.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3443362\" data-linked=\"BMO bullish on Gilead, sees 20% upside\" data-tweet=\"$GILD - BMO bullish on Gilead, sees 20% upside https://seekingalpha.com/news/3443362-bmo-bullish-on-gilead-sees-20-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3443362-bmo-bullish-on-gilead-sees-20-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443359\" data-ts=\"1552676436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443359-jury-awards-qualcomm-31_6m-in-apple-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jury awards Qualcomm $31.6M in Apple case</a></h4><ul><li>A jury awards Qualcomm (<a href='https://seekingalpha.com/symbol/QCOM' title='QUALCOMM Incorporated'>QCOM</a> <font color='green'>+1.5%</font>) $31.6M in damages after finding that Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+1.8%</font>) violated three of the company's patents.</li><li>The decision was from the first U.S. patent trial between the companies, who are battling in multiple countries.</li><li>Apple says it's disappointed with the verdict and calls Qualcomm's ongoing patent infringement claims an attempt to distract from QCOM's larger issues.</li><li>Source: Bloomberg First Word.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443359\" data-linked=\"Jury awards Qualcomm $31.6M in Apple case\" data-tweet=\"$QCOM $AAPL - Jury awards Qualcomm $31.6M in Apple case https://seekingalpha.com/news/3443359-jury-awards-qualcomm-31_6m-in-apple-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3443359-jury-awards-qualcomm-31_6m-in-apple-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>286&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443356\" data-ts=\"1552675685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTHT\" target=\"_blank\">HTHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443356-huazhu-groupplus-6_9-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huazhu Group +6.9% post Q4 results</a></h4><ul><li>Huazhu Group (<a href='https://seekingalpha.com/symbol/HTHT' title='Huazhu Group Limited'>HTHT</a> <font color=\"green\">+6.9%</font>) reports <a href=\"https://seekingalpha.com/pr/17445136-huazhu-group-limited-reports-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Q4</a> revenue growth of 20.6% Y/Y to $390.3M.</li><li>Net revenues from leased and owned hotels were $282.5M (+13.2% Y/Y); manachised and franchised hotels were $102.2M (+41.8% Y/Y).</li><li>For FY, adj. operating margin was 24.1%<i> &amp; </i>Adj. EBITDA margin was 32.5%..</li><li>The occupancy rate for all hotels in operation was 85.2%.</li><li>Huazhu opened 214 hotels, including 9 leased hotels and 205 manachised and franchised hotels.</li><li>Also, closed a total of 39 hotels, including 8 leased hotels and 31 manachised and franchised hotels.</li><li>The Company had 699 leased hotels, 3,309 manachised hotels, and 222 franchised hotels in operation in 391 cities.</li><li>The number of hotel rooms in operation totaled 422,747 (+11.3% Y/Y).</li><li>Operating cash inflow was $83.5M; cash, equivalents and restricted cash of $710.4M.</li><li>The Company had a total debt balance of $1.42B.</li><li><b>Q1 Outlook: </b>Net revenues to grow 13-15% Y/Y.</li><li><b>2019 Outlook:</b> Net revenues growth of 15-17%; gross hotel opening to 800-900, about 75% of which will be under midscale and upscale brands.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443060-huazhu-beats-0_04-beats-revenue\" target=\"_blank\">Huazhu beats by $0.04, beats on revenue</a> (Mar. 14 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443356\" data-linked=\"Huazhu Group +6.9% post Q4 results\" data-tweet=\"$HTHT - Huazhu Group +6.9% post Q4 results https://seekingalpha.com/news/3443356-huazhu-groupplus-6_9-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443356-huazhu-groupplus-6_9-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443354\" data-ts=\"1552675122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443354-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Avid Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a>) <font color=\"green\">+27%</font>. BroadVision (NASDAQ:<a href='https://seekingalpha.com/symbol/BVSN' title='BroadVision, Inc.'>BVSN</a>) <font color=\"green\">+14%</font>. CPS Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corporation'>CPSH</a>) <font color=\"green\">+12%</font>. Telaria (NYSE:<a href='https://seekingalpha.com/symbol/TLRA' title='Telaria, Inc.'>TLRA</a>) <font color=\"green\">+11%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Kopin Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a>) <font color=\"red\">-24%</font>. Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <font color=\"red\">-18%</font>. Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"red\">-17%</font>. SMTC Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTX' title='SMTC Corporation'>SMTX</a>) <font color=\"red\">-14%</font>. Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"red\">-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443354\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$AVID $BVSN $CPSH - Microcaps mostly among tech movers https://seekingalpha.com/news/3443354-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443354-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443353\" data-ts=\"1552674787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443353-ge-slips-not-worse-expected-enthusiasm-ebbs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE slips as &#39;not worse than expected&#39; enthusiasm ebbs</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a> <font color='red'>-2.5%</font>) shares give back a chunk of <a href=\"https://seekingalpha.com/news/3442857-ge-plus-3-percent-outlook-arguably-better-expected\" target=\"_blank\">yesterday's gains</a> as investors dissect the company\u2019s guidance that it may burn as much as $2B this year, a figure that many analysts said was not as bad as feared.</li><li><a href=\"https://finance.yahoo.com/news/ge-climb-worries-analysts-shares-165815782.html\" target=\"_blank\">GE bears are winning the day</a>, among them Gordon Haskett's John Inch, who says, \"Once the [qualitative] bullish analyst hype and the 'not worse than expected' enthusiasm begins to ebb and investors again put pen to paper, we expect GE\u2019s current overvalued stock price to trend lower toward a more normalized and realistic valuation.\"</li><li>\"GE\u2019s cash flow outlook remains mediocre at best, and no better than we had previously anticipated, despite ongoing billions of dollars spent on restructuring with seemingly not particularly compelling paybacks,\" Inch writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443353\" data-linked=\"GE slips as &#39;not worse than expected&#39; enthusiasm ebbs\" data-tweet=\"$GE - GE slips as &#39;not worse than expected&#39; enthusiasm ebbs https://seekingalpha.com/news/3443353-ge-slips-not-worse-expected-enthusiasm-ebbs?source=tweet\" data-url=\"https://seekingalpha.com/news/3443353-ge-slips-not-worse-expected-enthusiasm-ebbs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443350\" data-ts=\"1552673013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443350-ferrellgas-partners-and-smart-sand-among-energy-materials-gainers-phunware-and-mammoth-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ferrellgas Partners and Smart Sand among Energy/Materials gainers; Phunware and Mammoth Energy Services among losers</a></h4><ul><li><b>Gainers: </b>Ferrellgas Partners (NYSE:<a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners, L.P.'>FGP</a>) <font color=\"green\">+10%</font>. Smart Sand (NASDAQ:<a href='https://seekingalpha.com/symbol/SND' title='Smart Sand, Inc.'>SND</a>) <font color=\"green\">+8%</font>. Midstates Petroleum Company (NYSE:<a href='https://seekingalpha.com/symbol/MPO' title='Midstates Petroleum Company, Inc.'>MPO</a>) <font color=\"green\">+8%</font>. GCP Applied Technologies (NYSE:<a href='https://seekingalpha.com/symbol/GCP' title='GCP Applied Technologies Inc.'>GCP</a>) <font color=\"green\">+7%</font>. Oil-Dri Corporation of America (NYSE:<a href='https://seekingalpha.com/symbol/ODC' title='Oil-Dri Corporation of America'>ODC</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"red\">-19%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"red\">-14%</font>. Valhi (NYSE:<a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a>) <font color=\"red\">-8%</font>. Sanchez Midstream Partners (NYSEMKT:<a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a>) <font color=\"red\">-6%</font>. Rosehill Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443350\" data-linked=\"Ferrellgas Partners and Smart Sand among Energy/Materials gainers; Phunware and Mammoth Energy Services among losers\" data-tweet=\"$FGP $SND $AMPY - Ferrellgas Partners and Smart Sand among Energy/Materials gainers; Phunware and Mammoth Energy Services among losers https://seekingalpha.com/news/3443350-ferrellgas-partners-and-smart-sand-among-energy-materials-gainers-phunware-and-mammoth-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3443350-ferrellgas-partners-and-smart-sand-among-energy-materials-gainers-phunware-and-mammoth-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443344\" data-ts=\"1552672287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443344-vivendi-again-takes-aim-elliott-in-telecom-italia-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivendi again takes aim at Elliott in Telecom Italia fight</a></h4><ul>   <li>In a \"re-establishment of the truth,\" Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color=\"green\">+0.4%</font>) is <a href=\"https://www.vivendi.com/en/press/press-releases/vivendi-re-establishment-of-the-truth-after-the-tim-board-of-directors-meeting/\" target=\"_blank\">continuing to snipe</a> at the Elliott Management-backed directors of Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color=\"green\">+2.7%</font>) in their ongoing fight over control of the Italian incumbent.</li>    <li>\"Vivendi denounces the behavior of the Elliott-nominated Telecom Italia Board members who yesterday rejected by a majority vote the report issued by the company\u2019s Board of Statutory Auditors, a totally independent body, citing serious irregularities related to the company\u2019s governance and its Board,\" the company says.</li>    <li>\"Even the proxy advisory firms\" acknowledged misconduct, Vivendi says, though those firms are all <a href=\"https://seekingalpha.com/news/3442577-glass-lewis-joins-iss-opposing-vivendi-telecom-italia-vote\" target=\"_blank\">weighing in on Elliott's side</a> in the proxy fight.</li>    <li>Vivendi raises a number of specific, pointed governance questions in its statement, and urges shareholders to \"install a truly independent board.\"</li><li>It says only two of the boardmembers it's designated would not be independent, and that neither would run for chairman.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443344\" data-linked=\"Vivendi again takes aim at Elliott in Telecom Italia fight\" data-tweet=\"$VIVHY $TI $VIVEF - Vivendi again takes aim at Elliott in Telecom Italia fight https://seekingalpha.com/news/3443344-vivendi-again-takes-aim-elliott-in-telecom-italia-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3443344-vivendi-again-takes-aim-elliott-in-telecom-italia-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443324\" data-ts=\"1552668884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443324-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+210%</font>. Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"green\">+33%</font>. Catasys (NASDAQ:<a href='https://seekingalpha.com/symbol/CATS' title='Catasys, Inc.'>CATS</a>) <font color=\"green\">+26%</font>. Prana Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Limited'>PRAN</a>) <font color=\"green\">+24%</font>. Avid Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a>) <font color=\"green\">+23%</font>. Magenta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGTA' title='Magenta Therapeutics, Inc.'>MGTA</a>) <font color=\"green\">+22%</font>. Leap Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a>) <font color=\"green\">+14%</font>. Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>) <font color=\"green\">+13%</font>. CURO Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CURO' title='CURO Group Holdings Corp.'>CURO</a>) <font color=\"green\">+13%</font>. HyreCar (NASDAQ:<a href='https://seekingalpha.com/symbol/HYRE' title='HyreCar Inc.'>HYRE</a>) <font color=\"green\">+12%</font>.</li><li><strong>Losers:</strong> Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"red\">-42%</font>. Ra Medical Systems (NYSE:<a href='https://seekingalpha.com/symbol/RMED' title='Ra Medical Systems, Inc.'>RMED</a>) <font color=\"red\">-35%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHII' title='PHI, Inc.'>PHII</a>) <font color=\"red\">-34%</font>. BioScrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) <font color=\"red\">-32%</font>. Global Eagle Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/ENT' title='Global Eagle Entertainment Inc.'>ENT</a>) <font color=\"red\">-28%</font>. Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) <font color=\"red\">-27%</font>. Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-27%</font>. Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"red\">-26%</font>. Kopin (NASDAQ:<a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a>) <font color=\"red\">-25%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIIK' title='PHI, Inc.'>PHIIK</a>) <font color=\"red\">-23%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3443324\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SLNO $ACHV $CATS - Midday Gainers / Losers https://seekingalpha.com/news/3443324-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443324-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443323\" data-ts=\"1552668810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443323-curo-group-holdings-leads-financial-gainers-golden-bull-and-senmiao-technology-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CURO Group Holdings leads financial gainers; Golden Bull and Senmiao Technology among losers</a></h4><ul><li><b>Gainers:</b> CURO Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CURO' title='CURO Group Holdings Corp.'>CURO</a>) <font color=\"green\">+12%</font>. 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance, Inc.'>QFIN</a>) <font color=\"green\">+12%</font>. Malvern Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/MLVF' title='Malvern Bancorp, Inc.'>MLVF</a>) <font color=\"green\">+6%</font>. Severn Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/SVBI' title='Severn Bancorp, Inc.'>SVBI</a>) <font color=\"green\">+6%</font>. Landmark Infrastructure Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/LMRK' title='Landmark Infrastructure Partners LP'>LMRK</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"red\">-19%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-12%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-9%</font>. Impac Mortgage Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a>) <font color=\"red\">-7%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443323\" data-linked=\"CURO Group Holdings leads financial gainers; Golden Bull and Senmiao Technology among losers\" data-tweet=\"$CURO $QFIN $MLVF - CURO Group Holdings leads financial gainers; Golden Bull and Senmiao Technology among losers https://seekingalpha.com/news/3443323-curo-group-holdings-leads-financial-gainers-golden-bull-and-senmiao-technology-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443323-curo-group-holdings-leads-financial-gainers-golden-bull-and-senmiao-technology-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443315\" data-ts=\"1552667387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHII\" target=\"_blank\">PHII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443315-phi-inc-files-for-chapter-11-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PHI Inc. files for Chapter 11 bankruptcy</a></h4><ul><li>Helicopter servicer PHI Inc. (<a href='https://seekingalpha.com/symbol/PHII' title='PHI, Inc.'>PHII</a> <font color='red'>-31.6%</font>) <a href=\"https://seekingalpha.com/pr/17445278-phi-inc-takes-action-address-maturing-debt-strengthen-liquidity-balance-sheet-position\" target=\"_blank\">files for Chapter 11 bankruptcy protection</a> \"to address the upcoming maturity of PHI's unsecured senior notes and strengthen its balance sheet.\"</li><li>The company \"believes that its creditors and lessors will be supportive of PHI and its prospective business strategy and, to that end, anticipates filing a plan of reorganization in the early stages of the Chapter 11 process.\"</li><li>PHI says it hopes to emerge from bankruptcy this summer with a significantly reduced and more sustainable debt structure.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443315\" data-linked=\"PHI Inc. files for Chapter 11 bankruptcy\" data-tweet=\"$PHII - PHI Inc. files for Chapter 11 bankruptcy https://seekingalpha.com/news/3443315-phi-inc-files-for-chapter-11-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3443315-phi-inc-files-for-chapter-11-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443314\" data-ts=\"1552667294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRN\" target=\"_blank\">CTRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443314-citi-trendsminus-7_8-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi Trends -7.8% post Q4 results</a></h4><ul><li>Citi Trends (<a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a> <font color=\"red\">-7.8%</font>) reports comparable-store sales rose 0.2% in <a href=\"https://seekingalpha.com/pr/17445354-citi-trends-announces-fourth-quarter-and-full-year-2018-results\" target=\"_blank\">Q4</a>.</li><li>Citi Trends opened 19 new stores, relocated or expanded 8 other stores, and closed 6 stores in fiscal 2018.</li><li>The company executed on capital return program, returning $45M to shareholders in fiscal 2018.</li><li><strong>Q1 2019 Outlook:</strong> Comparable sales to decrease 8% for the first five-plus weeks and diluted EPS in the range of $0.83 to $0.87.</li><li><strong>2019 Outlook:</strong> EPS is expected in the range of $1.85 to $1.95; assuming comparable store sales increase in a range of 1%-2%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443115-citi-trends-beats-0_03-misses-revenue\" target=\"_blank\">Citi Trends beats by $0.03, misses on revenue</a> (Mar. 15 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443314\" data-linked=\"Citi Trends -7.8% post Q4 results\" data-tweet=\"$CTRN - Citi Trends -7.8% post Q4 results https://seekingalpha.com/news/3443314-citi-trendsminus-7_8-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443314-citi-trendsminus-7_8-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443305\" data-ts=\"1552665666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443305-eastman-kodak-and-reeds-among-consumer-gainers-iconix-brand-group-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eastman Kodak and Reed&#39;s among consumer gainers; Iconix Brand Group leads the losers</a></h4><ul><li><b>Gainers: </b>Reed's (NYSEMKT:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) <font color=\"green\">+8%</font>. Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Company'>KODK</a>) <font color=\"green\">+7%</font>. e.l.f. Beauty (NYSE:<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty, Inc.'>ELF</a>) <font color=\"green\">+6%</font>. BRF (NYSE:<a href='https://seekingalpha.com/symbol/BRFS' title='BRF S.A.'>BRFS</a>) <font color=\"green\">+6%</font>. Celsius Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-17%</font>. Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a>) <font color=\"red\">-9%</font>. Fuwei Films (NASDAQ:<a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a>) <font color=\"red\">-9%</font>. Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"red\">-6%</font>. Whirlpool (NYSE:<a href='https://seekingalpha.com/symbol/WHR' title='Whirlpool Corporation'>WHR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443305\" data-linked=\"Eastman Kodak and Reed&#39;s among consumer gainers; Iconix Brand Group leads the losers\" data-tweet=\"$REED $KODK $ELF - Eastman Kodak and Reed&#39;s among consumer gainers; Iconix Brand Group leads the losers https://seekingalpha.com/news/3443305-eastman-kodak-and-reeds-among-consumer-gainers-iconix-brand-group-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443305-eastman-kodak-and-reeds-among-consumer-gainers-iconix-brand-group-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443303\" data-ts=\"1552665313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTSI\" target=\"_blank\">UTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443303-utstarcomplus-4_8-after-narrowing-loss-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UTStarcom +4.8% after narrowing loss in Q4</a></h4><ul>   <li>UTStarcom (NASDAQ:<a href='https://seekingalpha.com/symbol/UTSI' title='UTStarcom Holdings Corp.'>UTSI</a>) is <font color=\"green\">up 4.8%</font> after Q4 earnings showed revenue declines in line with guidance along with growing gross margins.</li>    <li>Highly seasonal revenue fell 76% Q/Q, but was down 30% Y/Y and topped expectations (one estimates). That drop was due largely to timing of India project fulfillments along with lower outsourcing business.</li>    <li>Meanwhile net loss of $1M narrowed by $2.6M from last year.</li>    <li>Gross margin on equipment jumped to 60.3% from 27.4% on a higher mix of those revenues from Japan.</li>    <li>Revenue breakout: Equipment sales, $8.5M (down 33.6%); Services sales, $4.2M (down 22%).</li>    <li>Cash flow from operations was $4.3M; cash from investing was $1.2M; and cash used in financing was $0.5M. At Dec. 31, the company had liquidity of $73.7M.</li>    <li>For Q1, it's guiding to revenues of $20M-$25M.</li>    <li><a href=\"https://seekingalpha.com/article/4249025-utstarcom-holdings-corp-2018-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3443108-utstarcom-misses-0_01-beats-revenue\" target=\"_blank\">UTStarcom misses by $0.01, beats on revenue</a> (Mar. 15 2019)</li>   <li><a href=\"https://seekingalpha.com/pr/17445340-utstarcom-reports-unaudited-financial-results-fourth-quarter-full-year-2018\" target=\"_blank\">Press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3443303\" data-linked=\"UTStarcom +4.8% after narrowing loss in Q4\" data-tweet=\"$UTSI - UTStarcom +4.8% after narrowing loss in Q4 https://seekingalpha.com/news/3443303-utstarcomplus-4_8-after-narrowing-loss-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3443303-utstarcomplus-4_8-after-narrowing-loss-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443301\" data-ts=\"1552665081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRHC\" target=\"_blank\">QRHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443301-on-quest-resources-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Quest Resource&#39;s Q4 results</a></h4><ul><li>Quest Resource Holding (<a href='https://seekingalpha.com/symbol/QRHC' title='Quest Resource Holding Corporation'>QRHC</a>) reported Q4 revenue growth of 12.2% Y/Y to $25.26M,</li><li>Q4 Gross margin <font color=\"green\">improved by 392 bps</font> to 17.5%; and operating margin <font color=\"green\">recovered by 732 bps</font> to 0.77%.</li><li>SG&amp;A expenses were $3.89M up by 10.3%.</li><li>Adj. EBITDA improved by $1M to $771k, compared to negative $273k a year ago.</li><li>Company generated $3M in cash flow from operations YTD; and has Cash and cash equivalents of $2.12M as of December 31, 2018.</li><li>Management believes that their efforts have positioned the company well to grow sales at their targeted rate of 10% to 15% per year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442983-quest-resource-misses-revenue\" target=\"_blank\">Quest Resource misses on revenue</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443301\" data-linked=\"More on Quest Resource&#39;s Q4 results\" data-tweet=\"$QRHC - More on Quest Resource&#39;s Q4 results https://seekingalpha.com/news/3443301-on-quest-resources-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443301-on-quest-resources-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443298\" data-ts=\"1552664380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCM\" target=\"_blank\">SCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443298-stellus-capitalminus-3_9-after-stock-offering-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stellus Capital -3.9% after stock offering prices</a></h4><ul><li>Stellus Capital Management (NYSE:<a href='https://seekingalpha.com/symbol/SCM' title='Stellus Capital Investment Corporation'>SCM</a>) <font color=\"red\">falls 3.9%</font> to $14.14 after public offering of 2.75M shares<a href=\"https://seekingalpha.com/pr/17445726-stellus-capital-investment-corporation-prices-public-offering-common-stock\" target=\"_blank\"> prices</a> at $14.43 each.</li><li>Grants greenshoe option for up to 412,500 additional shares of common stock.</li><li>Expects net proceeds of $38.6M.</li><li>Agreed to bear 23.72 cents-per-share of underwriting discount in connection with the shared sold in the offering.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443005-stellus-capital-plans-stock-offering\" target=\"_blank\">Stellus Capital plans a stock offering</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443298\" data-linked=\"Stellus Capital -3.9% after stock offering prices\" data-tweet=\"$SCM - Stellus Capital -3.9% after stock offering prices https://seekingalpha.com/news/3443298-stellus-capitalminus-3_9-after-stock-offering-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3443298-stellus-capitalminus-3_9-after-stock-offering-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443296\" data-ts=\"1552664048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RLM\" target=\"_blank\">RLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443296-realm-up-10-on-shareholder-ok-on-asset-disposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Realm up 10% on shareholder OK on asset disposal</a></h4><ul><li>Thinly traded nano cap Realm Therapeutics (<a href='https://seekingalpha.com/symbol/RLM' title='Realm Therapeutics PLC'>RLM</a> <font color=\"green\">+9.6%</font>) is up, albeit on only 3,300 shares, following its <a href=\"https://seekingalpha.com/pr/17445758-realm-therapeutics-announces-result-general-meeting\" target=\"_blank\">announcement </a>that shareholders have voted in favor of its proposed asset disposal to Urgo, U.S. The transaction should close on March 28.</li><li>Shares will also be delisted from London stock exchange &#40;AIM&#41; on March 27.</li><li>The company imploded after lead candidate PR022 <a href=\"https://seekingalpha.com/news/3382397-realm-therapeutics-lead-candidate-flunks-mid-stage-atopic-dermatitis-study-shares-50-percent\" target=\"_blank\">failed </a>to beat placebo in a mid-stage eczema study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443296\" data-linked=\"Realm up 10% on shareholder OK on asset disposal\" data-tweet=\"$RLM - Realm up 10% on shareholder OK on asset disposal https://seekingalpha.com/news/3443296-realm-up-10-on-shareholder-ok-on-asset-disposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3443296-realm-up-10-on-shareholder-ok-on-asset-disposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443282\" data-ts=\"1552663320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443282-dosing-underway-in-mid-stage-study-of-lexicons-xermelo-in-biliary-tract-cancer-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dosing underway in mid-stage study of Lexicon&#39;s Xermelo in biliary tract cancer; shares up 4%</a></h4><ul><li>Lexicon Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a> <font color=\"green\">+3.8%</font>) is up on below-average volume in reaction to its <a href=\"https://seekingalpha.com/pr/17445764-lexicon-pharmaceuticals-announces-dosing-first-patient-tele-abc-study-phase-2a-clinical-study\" target=\"_blank\">announcement </a>that the first patient has been dosed in a Phase 2a clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03790111?titles=tele-abc&amp;lead=lexicon&amp;phase=1&amp;rank=1\" target=\"_blank\">TELE-ABC</a>, evaluating <a href=\"https://www.xermelo.com/\" target=\"_blank\">XERMELO </a>(telotristat ethyl) in patients with biliary tract cancer.</li><li>The open-label 54-subject study is assessing telotristat ethyl, combined first-line chemo (cisplatin + gemcitabine), in patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to tumor-directed therapy in the locally advanced or metastatic setting. The primary efficacy endpoint is progression-free survival &#40;PFS&#41; at month 6.</li><li>Topline data should be available in 2020.</li><li>Telotristat ethyl inhibits an enzyme called tryptophan hydroxylase that plays a key role in controlling the production of excess serotonin, a chemical that <a href=\"https://www.ommegaonline.org/article-details/The-Impact-of-the-Serotonin-on-the-Cause-and-Treatment-of-Cancer/1629\" target=\"_blank\">stimulates</a> aggressive cancers and carcinoids.</li><li>The FDA approved XERMELO in February 2017 for carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors who are inadequately controlled with somatostatin analog therapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443282\" data-linked=\"Dosing underway in mid-stage study of Lexicon&#39;s Xermelo in biliary tract cancer; shares up 4%\" data-tweet=\"$LXRX - Dosing underway in mid-stage study of Lexicon&#39;s Xermelo in biliary tract cancer; shares up 4% https://seekingalpha.com/news/3443282-dosing-underway-in-mid-stage-study-of-lexicons-xermelo-in-biliary-tract-cancer-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3443282-dosing-underway-in-mid-stage-study-of-lexicons-xermelo-in-biliary-tract-cancer-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443294\" data-ts=\"1552663291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443294-boeing-turns-green-on-report-of-737-max-software-upgrade-in-10-days\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing turns green on report of 737 MAX software upgrade in 10 days</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+0.9%</font>) shares spike higher to turn positive following reports that the company could roll out a <a href=\"https://twitter.com/AFP/status/1106573160844091393/photo/1\" target=\"_blank\">software upgrade</a> for its 737 MAX 8 jets in 10 days.</li><li>The report from Agence France-Presse comes after all 737 MAX jets were grounded following two fatal crashes; Boeing shares had slumped more than 10% as a result.</li><li>A Boeing spokesperson denies the AFP report, saying the software upgrade <a href=\"https://af.reuters.com/article/ethiopiaNews/idAFL1N2120T7\" target=\"_blank\">timeline has not changed</a> and that it will be rolled out \"in coming weeks.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3443294\" data-linked=\"Boeing turns green on report of 737 MAX software upgrade in 10 days\" data-tweet=\"$BA - Boeing turns green on report of 737 MAX software upgrade in 10 days https://seekingalpha.com/news/3443294-boeing-turns-green-on-report-of-737-max-software-upgrade-in-10-days?source=tweet\" data-url=\"https://seekingalpha.com/news/3443294-boeing-turns-green-on-report-of-737-max-software-upgrade-in-10-days\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>194&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443293\" data-ts=\"1552663178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CISN\" target=\"_blank\">CISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443293-cisionplus-2-on-top-pick-ahead-of-roadshow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cision +2% on Top Pick ahead of roadshow</a></h4><ul><li>Baird adds Cision (NYSE:<a href='https://seekingalpha.com/symbol/CISN' title='Cision Ltd.'>CISN</a>) to its Fresh Pick list ahead of next week's roadshow.</li><li>Earlier this month, Cision <a href=\"https://seekingalpha.com/news/3439518-cision-plus-7_3-percent-report-considering-sale\" target=\"_blank\">shares surged</a> after a Reuters report said the company was interested in a sale and talking to interested private equity firms. Cision is partially owned by PE firm GTCR.</li><li>CISN is <font color=\"green\">up 2%</font> to $13.54.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443293\" data-linked=\"Cision +2% on Top Pick ahead of roadshow\" data-tweet=\"$CISN - Cision +2% on Top Pick ahead of roadshow https://seekingalpha.com/news/3443293-cisionplus-2-on-top-pick-ahead-of-roadshow?source=tweet\" data-url=\"https://seekingalpha.com/news/3443293-cisionplus-2-on-top-pick-ahead-of-roadshow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443292\" data-ts=\"1552663103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443292-india-moves-to-block-juul\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">India moves to block Juul</a></h4><ul> <li>India's health ministry is raising concerns about Juul Labs (<a href='https://seekingalpha.com/symbol/JUUL' title='JUUL'>JUUL</a>), according to a Reuters exclusive.</li> <li>Juul products are called \"harmful\" and \"addictive\" in a <a href=\"http://news.trust.org//item/20190315145624-bup1u/\" target=\"_blank\">letter</a> from Health Secretary Preeti Sudan viewed by Reuters. Sudan wants Juul to be blocked from selling productions in the nation.</li> <li>Juul has stated previously that it's considering an entry into India.</li> <li>Altria (<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a>) has turned lower after the development.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443292\" data-linked=\"India moves to block Juul\" data-tweet=\"$JUUL $MO - India moves to block Juul https://seekingalpha.com/news/3443292-india-moves-to-block-juul?source=tweet\" data-url=\"https://seekingalpha.com/news/3443292-india-moves-to-block-juul\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443291\" data-ts=\"1552662771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTX\" target=\"_blank\">MNTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443291-on-manitex-internationals-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Manitex International&#39;s Q4 results</a></h4><ul><li>Manitex International (<a href='https://seekingalpha.com/symbol/MNTX' title='Manitex International, Inc.'>MNTX</a> <font color=\"red\">-0.3%</font>) reported Q4 revenues of $60.6M down by 6% Y/Y.</li><li>Q4 Gross margin <font color=\"red\">declined by 174 bps</font> to 14.1%.</li><li>Q4 operating loss was $6.41M, compared to operating income of $765k a year ago.</li><li>Adj. EBITDA increased by 12.8% Y/Y to $3.53M, and margin <font color=\"green\">improved by 97 bps</font> to 5.8%.</li><li>Backlog was at $80M as of February 28, 2019, compared with $61M as of year-end 2017, representing a 30% increase.</li><li>Book to bill ratio was 1.10:1 for the quarter.</li><li>In January 2019 Manitex signed framework for a commercial agreement with Tadano covering the Asian markets and in February received from Tadano an initial small stocking order for the Asian markets.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442979-manitex-misses-0_02-misses-revenue\" target=\"_blank\">Manitex misses by $0.02, misses on revenue</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443291\" data-linked=\"More on Manitex International&#39;s Q4 results\" data-tweet=\"$MNTX - More on Manitex International&#39;s Q4 results https://seekingalpha.com/news/3443291-on-manitex-internationals-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443291-on-manitex-internationals-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443288\" data-ts=\"1552662698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIDM\" target=\"_blank\">CIDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443288-cinedigm-rallies-after-acquiring-future-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cinedigm rallies after acquiring Future Today</a></h4><ul> <li>Cinedigm (<a href='https://seekingalpha.com/symbol/CIDM' title='Cinedigm Corp.'>CIDM</a> <font color='green'>+8.6%</font>) strikes a deal to acquire OTT platform Future Today for $45M in cash and $15M in Cinedigm stock.</li><li>The company says the acquisition increases Cinedigm's OTT footprint to over 7.6M monthly active users and 67M total app installs.</li><li>The deal is expected to be immediately accretive.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17445694-cinedigm-acquire-future-today-inc\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443288\" data-linked=\"Cinedigm rallies after acquiring Future Today\" data-tweet=\"$CIDM - Cinedigm rallies after acquiring Future Today https://seekingalpha.com/news/3443288-cinedigm-rallies-after-acquiring-future-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3443288-cinedigm-rallies-after-acquiring-future-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443283\" data-ts=\"1552662277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443283-achieve-life-sciences-and-karyopharm-therapeutics-among-healthcare-gainers-biocept-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip  among losers</a></h4><ul><li><b>Gainers: </b>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+249%</font>. Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"green\">+42%</font>. Catasys (NASDAQ:<a href='https://seekingalpha.com/symbol/CATS' title='Catasys, Inc.'>CATS</a>) <font color=\"green\">+23%</font>. Karyopharm Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) <font color=\"green\">+23%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers: </b>Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"red\">-37%</font>. BioScrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) <font color=\"red\">-30%</font>. Ra Medical Systems (NYSE:<a href='https://seekingalpha.com/symbol/RMED' title='Ra Medical Systems, Inc.'>RMED</a>) <font color=\"red\">-29%</font>. Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-26%</font>. Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"red\">-22%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443283\" data-linked=\"Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip  among losers\" data-tweet=\"$SLNO $ACHV $CATS - Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip among losers https://seekingalpha.com/news/3443283-achieve-life-sciences-and-karyopharm-therapeutics-among-healthcare-gainers-biocept-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3443283-achieve-life-sciences-and-karyopharm-therapeutics-among-healthcare-gainers-biocept-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443277\" data-ts=\"1552661969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICHR\" target=\"_blank\">ICHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443277-ichorplus-6-needham-sees-growing-momentum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ichor +6% as Needham sees &quot;growing momentum&quot;</a></h4><ul><li>Needham sees \"growing momentum\" behind Ichor's (NASDAQ:<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a>) initiative to drive incremental revenue growth through market share gains.</li><li>The comments follow Ichor and Needham's non-deal roadshow with management reiterating its belief that excess component inventory will be \"largely clear\" by quarter's end.</li><li>Ichor sees fab equipment demand \"bouncing along the bottom\" in H1 with a \"modest uptick\" following in H2.</li><li>Needham reiterates its Buy rating and $27 PT.</li><li>Ichor shares are<font color=\"green\"> up 6.3%</font> to $21.86.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443260-semis-gain-bottom-call-nand-orders\" target=\"_blank\">Semis gain on bottom call, NAND orders</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443277\" data-linked=\"Ichor +6% as Needham sees &quot;growing momentum&quot;\" data-tweet=\"$ICHR - Ichor +6% as Needham sees &quot;growing momentum&quot; https://seekingalpha.com/news/3443277-ichorplus-6-needham-sees-growing-momentum?source=tweet\" data-url=\"https://seekingalpha.com/news/3443277-ichorplus-6-needham-sees-growing-momentum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443272\" data-ts=\"1552661795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCKT\" target=\"_blank\">RCKT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443272-rocket-pharma-up-8-ahead-of-presentations-acc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket Pharma up 8% ahead of presentations at ACC</a></h4><ul><li>Rocket Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RCKT' title='Rocket Pharmaceuticals, Inc.'>RCKT</a> <font color=\"green\">+8.3%</font>) is up on average volume ahead of <a href=\"https://seekingalpha.com/pr/17445446-rocket-pharmaceuticals-announces-presentations-american-college-cardiology-2019-annual\" target=\"_blank\">presentations </a>on gene therapy RP-A501 in patients with <a href=\"https://ghr.nlm.nih.gov/condition/danon-disease\" target=\"_blank\">Danon disease</a>, a rare inherited disorder characterized by weakening of heart and skeletal muscles.</li><li>Preclinical data will be presented on Sunday, March 17, and Monday, March 18, at the AAC Annual Scientific Session &amp; Expo in New Orleans.</li><li>The company says clinical development will start next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443272\" data-linked=\"Rocket Pharma up 8% ahead of presentations at ACC\" data-tweet=\"$RCKT - Rocket Pharma up 8% ahead of presentations at ACC https://seekingalpha.com/news/3443272-rocket-pharma-up-8-ahead-of-presentations-acc?source=tweet\" data-url=\"https://seekingalpha.com/news/3443272-rocket-pharma-up-8-ahead-of-presentations-acc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443275\" data-ts=\"1552661490\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELF\" target=\"_blank\">ELF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443275-comeback-bid-continues-for-e-l-f-beauty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comeback bid continues for e.l.f. Beauty</a></h4><ul> <li>Shares of e.l.f. Beauty (<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty, Inc.'>ELF</a> <font color='green'>+5.3%</font>) rally again and are now up 12.2% for the week on improved sentiment following a post-earnings slide.</li> <li>Today's buying action could also be linked to a strong earnings from within the sector by Ulta Beauty.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3442974-ulta-beauty-plus-4-percent-strong-q4-sales\" target=\"_blank\">Ulta Beauty +4% after strong Q4 sales</a> (March 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443275\" data-linked=\"Comeback bid continues for e.l.f. Beauty\" data-tweet=\"$ELF - Comeback bid continues for e.l.f. Beauty https://seekingalpha.com/news/3443275-comeback-bid-continues-for-e-l-f-beauty?source=tweet\" data-url=\"https://seekingalpha.com/news/3443275-comeback-bid-continues-for-e-l-f-beauty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443270\" data-ts=\"1552660750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443270-litigation-risk-seen-increased-for-firearms-industry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Litigation risk seen increased for firearms industry</a></h4><ul> <li>CL King calls the Connecticut Supreme Court's ruling that Remington can be sued over the Sandy Hook shooting \"another negative overhang\" on the firearms industry.</li> <li>Analyst Scott Stember says gun makers American Outdoor Brands (<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='green'>+3.1%</font>) and Sturm, Ruger (<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company, Inc.'>RGR</a> <font color='green'>+1.2%</font>) could face additional litigation costs in the future due to the ruling.</li> <li>While the pair are gaining today following the <a href=\"https://seekingalpha.com/news/3443174-gunmaker-shares-rise-new-zealand-shootings\" target=\"_blank\">shootings</a> in New Zealand, shares of AOBC are down 25% YTD and Sturm, Ruger is off 5%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443270\" data-linked=\"Litigation risk seen increased for firearms industry\" data-tweet=\"$AOBC $RGR - Litigation risk seen increased for firearms industry https://seekingalpha.com/news/3443270-litigation-risk-seen-increased-for-firearms-industry?source=tweet\" data-url=\"https://seekingalpha.com/news/3443270-litigation-risk-seen-increased-for-firearms-industry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443268\" data-ts=\"1552660597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVID\" target=\"_blank\">AVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443268-avidplus-30-on-upside-fy19-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avid +30% on upside FY19 outlook</a></h4><ul><li>Avid Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a>) <font color=\"green\">gains 30% </font>after yesterday's Q4 results missed on EPS, beat on revenue, and included upside guidance.</li><li>The Q1 outlook has revenue from $96M to $104M (consensus: $100.5M) and adjusted EBITDA from $7M to $12M (consensus: $9.1M).</li><li>FY19 guidance has revenue from $420M to $430M (consensus: $423M) and adjusted EBITDA from $60M to $65M (consensus: $46.7M).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443026-avid-misses-0_02-beats-revenue\" target=\"_blank\">Avid misses by $0.02, beats on revenue</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443268\" data-linked=\"Avid +30% on upside FY19 outlook\" data-tweet=\"$AVID - Avid +30% on upside FY19 outlook https://seekingalpha.com/news/3443268-avidplus-30-on-upside-fy19-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3443268-avidplus-30-on-upside-fy19-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443267\" data-ts=\"1552660465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLD\" target=\"_blank\">CLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443267-cloud-peak-energyminus-11-after-issuing-going-concern-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloud Peak Energy -11% after issuing going concern warning</a></h4><ul><li>Cloud Peak Energy (<a href='https://seekingalpha.com/symbol/CLD' title='Cloud Peak Energy Inc.'>CLD</a> <font color=\"red\">-11.1%</font>) plunges after disclosing that it has substantial doubt about its <a href=\"https://www.sec.gov/Archives/edgar/data/1441849/000110465919014968/a19-30091_110k.htm\" target=\"_blank\">ability to continue as a going concern</a>.</li><li>CLD says its updated financial  forecasts reflect significantly lower levels of expected cash flow from operating activities for 2019, in part due to ongoing production problems at the Antelope mine and weaker overall customer demand, particularly for coal from the Cordero Rojo mine.</li><li>CLD reiterates that it needs to restructure its balance sheet to improve its capital structure, adjust to ongoing depressed Powder River Basin thermal coal industry conditions, address its significantly reduced liquidity and continue as a going concern; an interest payment on 2024 notes will need to be made by April 14 to avoid default.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443267\" data-linked=\"Cloud Peak Energy -11% after issuing going concern warning\" data-tweet=\"$CLD $CLDPQ - Cloud Peak Energy -11% after issuing going concern warning https://seekingalpha.com/news/3443267-cloud-peak-energyminus-11-after-issuing-going-concern-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3443267-cloud-peak-energyminus-11-after-issuing-going-concern-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443262\" data-ts=\"1552660092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MELI\" target=\"_blank\">MELI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443262-stifel-calls-top-to-mercadolibre-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel calls a top to MercadoLibre rally</a></h4><ul> <li>MercadoLibre (<a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a> <font color='red'>-0.6%</font>) trades slightly lower after Stifel drops its rating to Hold from Buy on a call tied to valuation.</li> <li>The price target on MELI is adjusted to $500 from $460.</li> <li>Shares of MercadolIbre are up 67% YTD, peaking at $514.90 earlier this week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443262\" data-linked=\"Stifel calls a top to MercadoLibre rally\" data-tweet=\"$MELI - Stifel calls a top to MercadoLibre rally https://seekingalpha.com/news/3443262-stifel-calls-top-to-mercadolibre-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3443262-stifel-calls-top-to-mercadolibre-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443260\" data-ts=\"1552659975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443260-semis-gain-on-bottom-call-nand-orders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semis gain on bottom call, NAND orders</a></h4><ul><li>Semis gain after Broadcom <a href=\"https://seekingalpha.com/article/4248944-broadcom-inc-avgo-ceo-hock-tan-q1-2019-results-earnings-call-transcript\" target=\"_blank\">called for a bottom</a> in the semi business in Q2 and Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='green'>+5.6%</font>) received a Citi target bump from $177 to $215 citing a recent pickup in NAND equipment orders.</li><li>On the move: Ichor (<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+6.5%</font>), MKS Instruments (<a href='https://seekingalpha.com/symbol/MKSI' title='MKS Instruments, Inc.'>MKSI</a> <font color='green'>+5.9%</font>), STMicroelectronics (<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics N.V.'>STM</a> <font color='green'>+5.4%</font>), Ultra Clean (<a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color='green'>+5.2%</font>), Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='green'>+4.4%</font>), Skyworks (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+4.3%</font>), Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a> <font color='green'>+2.9%</font>), Lumentum (<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='green'>+4.1%</font>), Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+2.8%</font>).</li><li>The Philadelphia Semiconductor Index is <font color=\"green\">up 3.3%</font>.</li><li>Related semi ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443260\" data-linked=\"Semis gain on bottom call, NAND orders\" data-tweet=\"$LRCX $LRCX $ICHR - Semis gain on bottom call, NAND orders https://seekingalpha.com/news/3443260-semis-gain-on-bottom-call-nand-orders?source=tweet\" data-url=\"https://seekingalpha.com/news/3443260-semis-gain-on-bottom-call-nand-orders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443259\" data-ts=\"1552659586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTEK\" target=\"_blank\">FTEK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443259-fuel-techplus-7-post-q4-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fuel Tech +7% post Q4 revenue beat</a></h4><ul><li>Fuel Tech (<a href='https://seekingalpha.com/symbol/FTEK' title='Fuel Tech, Inc.'>FTEK</a> <font color=\"green\">+7.4%</font>) reported Q4 revenue growth of 18.2% Y/Y to $15.8M, with Air Pollution Control segment revenues of $10.54M (+11.5% Y/Y) and FUEL CHEM segment revenues of $5.28M (+34.6% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">declined by 470 bps</font> to 37.3%.</li><li>Adj. EBITDA increased by 116.3% Y/Y to $1.21M and Adj. EBITDA margin <font color=\"green\">improved by 346 bps</font> to 7.6%.</li><li>SG&amp;A expenses were $4.78M (-2.3% Y/Y), or 30.2% of revenues, down by 630 bps.</li><li>Capital projects backlog was at $12.4M ($11M domestic), as of December 31, 2018.</li><li>Net cash provided by operating activities was $4.93M, compared to cash used $3.57M a year ago.</li><li>Company had cash, cash equivalents and restricted of $18.06M, as of December 31, 2018.</li><li>Fuel Tech has commenced the process of suspending operations in China and expect that it will be completed by the end of Q2 2019. For FY18 Beijing Fuel Tech generated an operating loss of $1.9M and revenues of just $3M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442950-fuel-tech-beats-revenue\" target=\"_blank\">Fuel Tech beats on revenue</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443259\" data-linked=\"Fuel Tech +7% post Q4 revenue beat\" data-tweet=\"$FTEK - Fuel Tech +7% post Q4 revenue beat https://seekingalpha.com/news/3443259-fuel-techplus-7-post-q4-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3443259-fuel-techplus-7-post-q4-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443258\" data-ts=\"1552659251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMED\" target=\"_blank\">RMED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443258-ra-medical-down-28-on-soft-q1-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ra Medical down 28% on soft Q1 guidance</a></h4><ul><li>Thinly traded nano cap Ra Medical Systems (<a href='https://seekingalpha.com/symbol/RMED' title='Ra Medical Systems, Inc.'>RMED</a> <font color=\"red\">-27.7%</font>) is down on modestly higher volume following its <a href=\"https://seekingalpha.com/pr/17444898-ra-medical-systems-reports-2018-fourth-quarter-full-year-financial-results\" target=\"_blank\">Q4 report</a> released after the close yesterday.</li><li>Revenue came in slightly below expectations but investors appear to be reacting to its Q1 estimate of $1.0M - 1.4M, well below consensus of $4M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442982-ra-medical-systems-misses-revenue\" target=\"_blank\">Ra Medical Systems misses on revenue</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443258\" data-linked=\"Ra Medical down 28% on soft Q1 guidance\" data-tweet=\"$RMED - Ra Medical down 28% on soft Q1 guidance https://seekingalpha.com/news/3443258-ra-medical-down-28-on-soft-q1-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3443258-ra-medical-down-28-on-soft-q1-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443247\" data-ts=\"1552658557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443247-kandi-gains-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi gains after earnings</a></h4><ul> <li>Kandi Technologies (<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+1.6%</font>) says revenue increased <a href=\"https://seekingalpha.com/pr/17445408-kandi-technologies-reports-full-year-2018-financial-results\" target=\"_blank\">9.4%</a> in 2019 to $112M.</li> <li>Gross margin was up 41% to $20.2M to rep 18.0% of sales.</li> <li>Kandi reduced its operating loss for the year to $1.6M from $26.1M in 2017.</li> <li>Looking ahead, Kandi says it aims to produce and sell 20K EVs in 2019 and obtain the approval of its application for a manufacturing license from the Ministry of Industry and Information Technology to become an official EV manufacturing enterprise with \"dual production licenses.\" Management also notes that Kandi EV models are now eligible in the U.S. for up to $7.5K in federal tax credits in 2019 and 2020.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443128-kandi-technologies-reports-fy-results\" target=\"_blank\">Kandi Technologies reports FY results</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443247\" data-linked=\"Kandi gains after earnings\" data-tweet=\"$KNDI - Kandi gains after earnings https://seekingalpha.com/news/3443247-kandi-gains-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3443247-kandi-gains-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443236\" data-ts=\"1552657255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443236-pareteumplus-3_1-on-17m-in-new-contracts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +3.1% on $17M in new contracts</a></h4><ul>   <li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color=\"green\">3.1% higher</font> out of today's open after announcing <a href=\"https://seekingalpha.com/pr/17445374-pareteum-wins-17-million-new-early-march-contracts\" target=\"_blank\">$17M in early March contracts from 10 new customers</a>.</li>    <li>Those include a cloud communications platform and connectivity services deal for a European mobile virtual network operator; a cloud communications platform for a U.S. provider of connected wearable devices; a short message service solution for a global SMS provider in Hong Kong; and an SMS solution for a digital agency based in West Africa.</li>    <li>\"We are seeing a fantastic response to our enhanced and expanded offering across all sectors,\" says Chief Revenue Officer Rob Mumby.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443236\" data-linked=\"Pareteum +3.1% on $17M in new contracts\" data-tweet=\"$TEUM - Pareteum +3.1% on $17M in new contracts https://seekingalpha.com/news/3443236-pareteumplus-3_1-on-17m-in-new-contracts?source=tweet\" data-url=\"https://seekingalpha.com/news/3443236-pareteumplus-3_1-on-17m-in-new-contracts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443228\" data-ts=\"1552656574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443228-cree-sells-lighting-products-for-310m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree sells Lighting Products for $310M</a></h4><ul><li>Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) will sell its Lighting Products business unit to Ideal Industries for about $310M before tax impacts.</li><li>Cree expects to receive an initial cash payment of $225M with the potential for targeted earn-out payments of about $85M over a 12-month period that starts two years after the transaction closes.</li><li>Guidance update: Q3 revenue from continuing operations is expected between $271M and $277M with Wolfspeed sales of $139M to $141M and LED sales of $132M to $136M.</li><li>Non-GAAP gross margin expected at 36% and EPS from $0.14 to $0.18.</li><li>Cree will hold a call on Monday at 8:30 AM ET to discuss the sale and guidance update with a webcast available<a href=\"https://seekingalpha.com/pr/17445643-cree-sell-lighting-business-ideal-industries-inc\" target=\"_blank\"> here</a>.</li><li>Cree shares are <font color=\"green\">up 2.8%</font> pre-market to $55.06.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443228\" data-linked=\"Cree sells Lighting Products for $310M\" data-tweet=\"$CREE - Cree sells Lighting Products for $310M https://seekingalpha.com/news/3443228-cree-sells-lighting-products-for-310m?source=tweet\" data-url=\"https://seekingalpha.com/news/3443228-cree-sells-lighting-products-for-310m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443227\" data-ts=\"1552656540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATVI\" target=\"_blank\">ATVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443227-activisionplus-1_8-piper-says-valuation-looks-attractive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activision +1.8% as Piper says valuation looks attractive</a></h4><ul>   <li>Activision Blizzard (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a>) is <font color=\"green\">up 1.8%</font> premarket after Piper Jaffray suggests investors look at \"chipping away\" at a position after recent declines.</li>    <li>The stock is down nearly 50% over six months and \"investors should be 'kicking the tires' given an improving setup in late '19 and 2020,\" writes analyst Michael Olson, who sees a low bar on guidance and many reasons for optimism aside from valuation, including refocus on key franchises and potential E3 announcements around a mobile take on <i>Call of Duty.</i> (h/t Bloomberg)</li>    <li>Piper is Overweight on the stock with a price target of $52, implying 20% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443227\" data-linked=\"Activision +1.8% as Piper says valuation looks attractive\" data-tweet=\"$ATVI - Activision +1.8% as Piper says valuation looks attractive https://seekingalpha.com/news/3443227-activisionplus-1_8-piper-says-valuation-looks-attractive?source=tweet\" data-url=\"https://seekingalpha.com/news/3443227-activisionplus-1_8-piper-says-valuation-looks-attractive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443224\" data-ts=\"1552656369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443224-biocept-down-23-on-pricing-8_2m-registered-direct-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept down 23% on pricing $8.2M registered direct offering</a></h4><ul> <li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) has <a href=\"https://seekingalpha.com/pr/17445678-biocept-announces-pricing-8_2-million-registered-direct-offering\" target=\"_blank\">entered</a> into a securities purchase agreement to purchase ~$8.2M common stock in a registered direct offering and warrants to purchase common shares in a concurrent private placement.</li><li>The combined purchase price for one share of common stock and each warrant will be $1.37.</li>                  <li>Under the terms of the purchase agreement, Biocept has agreed to sell and issue ~5.95M common shares and warrants, respectively.</li><li>Closing date is March 19.</li><li>Shares are up <font color=\"red\">23%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443224\" data-linked=\"Biocept down 23% on pricing $8.2M registered direct offering\" data-tweet=\"$BIOC - Biocept down 23% on pricing $8.2M registered direct offering https://seekingalpha.com/news/3443224-biocept-down-23-on-pricing-8_2m-registered-direct-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3443224-biocept-down-23-on-pricing-8_2m-registered-direct-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443220\" data-ts=\"1552656153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443220-avgo-bdsi-and-nvln-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVGO, BDSI and NVLN among premarket gainers</a></h4><ul><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"green\">+77%</font> on <a href=\"https://seekingalpha.com/news/3443179-achieve-life-sciences-83-percent-advancement-cytisinicline\" target=\"_blank\">advancement</a> of cytisinicline.</li><li>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+62%</font> on <a href=\"https://seekingalpha.com/news/3443191-soleno-44-percent-premarket-continuation-dccr-study\" target=\"_blank\">continuation</a> of DCCR study.</li><li>MDC Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCA' title='MDC Partners Inc.'>MDCA</a>) <font color=\"green\">+23%</font> on <a href=\"https://seekingalpha.com/news/3443127-mdc-partners-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Karyopharm Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) <font color=\"green\">+23%</font> on <a href=\"https://seekingalpha.com/news/3443168-karyopharm-17-percent-premarket-extension-review-period-selinexor\" target=\"_blank\">extension</a> of review period for selinexor</li><li>Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences, Inc.'>RKDA</a>) <font color=\"green\">+23%</font> on <a href=\"https://seekingalpha.com/news/3443178-arcadia-biosciences-plus-26-percent-receiving-fda-approval-sonova-gla-safflower-oil\" target=\"_blank\">receiving</a> FDA approval for SONOVA GLA safflower oil.</li><li>Novelion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NVLN' title='Novelion Therapeutics Inc.'>NVLN</a>) <font color=\"green\">+22%</font> on <a href=\"https://seekingalpha.com/news/3443042-novelion-therapeutics-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>BioScrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) <font color=\"green\">+20%</font> on <a href=\"https://seekingalpha.com/news/3443129-bioscrip-misses-0_15-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Leap Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a>) <font color=\"green\">+9%</font>.</li><li>BioDelivery Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3442959-biodelivery-sciences-eps-line-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Huazhu Group (NASDAQ:<a href='https://seekingalpha.com/symbol/HTHT' title='Huazhu Group Limited'>HTHT</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3443060-huazhu-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>SMTC (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTX' title='SMTC Corporation'>SMTX</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3443056-smtc-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>TRACON Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TCON' title='TRACON Pharmaceuticals, Inc.'>TCON</a>) <font color=\"green\">+3%</font>.</li><li>Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) <font color=\"green\">+6%</font>.</li><li>Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/news/3442969-broadcom-beats-0_32-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443220\" data-linked=\"AVGO, BDSI and NVLN among premarket gainers\" data-tweet=\"$ACHV $SLNO $MDCA - AVGO, BDSI and NVLN among premarket gainers https://seekingalpha.com/news/3443220-avgo-bdsi-and-nvln-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443220-avgo-bdsi-and-nvln-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443219\" data-ts=\"1552655963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443219-kirk-and-frsx-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KIRK and FRSX among premarket losers</a></h4><ul><li>Kopin (NASDAQ:<a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a>) <font color=\"red\">-24%</font> on <a href=\"https://seekingalpha.com/news/3443062-kopin-minus-16-percent-secondary-offering\" target=\"_blank\">secondary offering</a>.</li><li>PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHIIK' title='PHI, Inc.'>PHIIK</a>) <font color=\"red\">-23%</font>.</li><li>Yield10 Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a>) <font color=\"red\">-19%</font>.</li><li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-23%</font>.</li><li>Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"red\">-19%</font> on <a href=\"https://seekingalpha.com/pr/17445021-foresight-autonomous-holdings-ltd-announces-proposed-public-offering-american-depositary\" target=\"_blank\">announcing</a> public offering of ADS.</li><li>Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"red\">-21%</font>.</li><li>Kirkland's (NASDAQ:<a href='https://seekingalpha.com/symbol/KIRK' title='Kirkland&#39;s, Inc.'>KIRK</a>) <font color=\"red\">-13%</font> on <a href=\"https://seekingalpha.com/news/3443113-kirklands-eps-line-misses-revenue\" target=\"_blank\">FY earnings</a>.</li><li>Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3442968-turtle-beach-beats-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Ritter Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals, Inc.'>RTTR</a>) <font color=\"red\">-12%</font>.</li><li>BioTime (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTX' title='BioTime, Inc.'>BTX</a>) <font color=\"red\">-16%</font> on <a href=\"https://seekingalpha.com/news/3442993-biotime-misses-0_28-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3443141-diplomat-pharmacy-eps-4_00\" target=\"_blank\">Q4 earnings</a>.</li><li>Genprex (NASDAQ:<a href='https://seekingalpha.com/symbol/GNPX' title='Genprex, Inc.'>GNPX</a>) <font color=\"red\">-11%</font>.</li><li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3442977-ascena-retail-group-misses-0_01-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) <font color=\"red\">-9%</font> in response to its <a href=\"https://seekingalpha.com/news/3443137-spectrum-withdraws-u-s-marketing-application-rolontis-shares-8-percent-premarket\" target=\"_blank\">withdrawal</a> of its U.S. marketing application seeking approval for ROLONTIS.</li><li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"red\">-8%</font>.</li><li>Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd'>KTOV</a>) <font color=\"red\">-11%</font>.</li><li>Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"red\">-9%</font>.</li><li>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"red\">-7%</font>.</li><li>Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics, Inc.'>SEEL</a>) <font color=\"red\">-6%</font>.</li><li>Pivotal Software (NYSE:<a href='https://seekingalpha.com/symbol/PVTL' title='Pivotal Software, Inc.'>PVTL</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3443008-pivotal-software-beats-0_02-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443219\" data-linked=\"KIRK and FRSX among premarket losers\" data-tweet=\"$KOPN $PHIIK $YTEN - KIRK and FRSX among premarket losers https://seekingalpha.com/news/3443219-kirk-and-frsx-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443219-kirk-and-frsx-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443215\" data-ts=\"1552655646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443215-matinas-bio-prices-stock-offering-1_10-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas Bio prices stock offering at $1.10; shares down 6% premarket</a></h4><ul><li>Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) is down <font color=\"red\">6%</font> premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17445570-matinas-biopharma-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~27.3M shares of common stock at $1.10 per share. Underwriters over-allotment is an additional ~4.1M shares. Closing date is March 19.</li><li>Yesterday's close was $1.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443215\" data-linked=\"Matinas Bio prices stock offering at $1.10; shares down 6% premarket\" data-tweet=\"$MTNB - Matinas Bio prices stock offering at $1.10; shares down 6% premarket https://seekingalpha.com/news/3443215-matinas-bio-prices-stock-offering-1_10-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3443215-matinas-bio-prices-stock-offering-1_10-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443213\" data-ts=\"1552655535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YTRA\" target=\"_blank\">YTRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443213-yatra-enters-due-diligence-ebix-ytraplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yatra enters due diligence with Ebix; YTRA +4%</a></h4><ul><li>Yatra Online (NASDAQ:<a href='https://seekingalpha.com/symbol/YTRA' title='Yatra Online, Inc.'>YTRA</a>) <a href=\"https://seekingalpha.com/pr/17445383-yatra-online-enters-mutual-confidentiality-agreement-ebix-consider-ebixs-proposal\" target=\"_blank\">announces</a> entering into a mutual confidential agreement with Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix, Inc.'>EBIX</a>) to commence due diligence and so Yatra can further review and consider the acquisition proposal.</li><li>Citigroup Global Markets is acting as Yatra's financial advisor.</li><li>Yatra shares are <font color=\"green\">up 4.2%</font> pre-market to $5.21.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3441511-yatra-plus-38-percent-ebix-buyout-offer\" target=\"_blank\">Yatra +38% on Ebix buyout offer</a> (March 11)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3441591-yatra-online-confirms-considers-ebix-offer\" target=\"_blank\">Yatra Online confirms, considers Ebix offer</a> (March 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443213\" data-linked=\"Yatra enters due diligence with Ebix; YTRA +4%\" data-tweet=\"$YTRA $EBIX - Yatra enters due diligence with Ebix; YTRA +4% https://seekingalpha.com/news/3443213-yatra-enters-due-diligence-ebix-ytraplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3443213-yatra-enters-due-diligence-ebix-ytraplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443212\" data-ts=\"1552655466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443212-nucorminus-3-after-forecasting-q1-earnings-below-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucor -3% after forecasting Q1 earnings below expectations</a></h4><ul><li>Nucor (NYSE:<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a>) <font color=\"red\">-3.1%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17445649-nucor-announces-guidance-first-quarter-2019-earnings\" target=\"_blank\">issuing below consensus guidance</a> for Q1 EPS of $1.45-$1.50 vs. $1.62 analyst consensus estimate; EPS was $2.07 in Q4 and $1.10 in the year-ago quarter.</li><li>NUE expects Q1 earnings in the steel mills segment to decline from Q4 2018 due primarily to lower  average selling prices and margins in the sheet mill group.</li><li>But the company believes sheet pricing \"reached the low point\" during Q1 and  says it is encouraged by the impact of recent price increases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443212\" data-linked=\"Nucor -3% after forecasting Q1 earnings below expectations\" data-tweet=\"$NUE - Nucor -3% after forecasting Q1 earnings below expectations https://seekingalpha.com/news/3443212-nucorminus-3-after-forecasting-q1-earnings-below-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3443212-nucorminus-3-after-forecasting-q1-earnings-below-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443211\" data-ts=\"1552655343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443211-fda-accepts-adamis-pharmas-application-for-higher-dose-naloxone-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Adamis Pharma&#39;s application for higher dose naloxone; shares up 2% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17445027-adamis-pharmaceuticals-announces-fda-acceptance-review-new-drug-application-higher-dose\" target=\"_blank\">accepts for review</a> Adamis Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) marketing application seeking approval for its higher dose naloxone injection for the treatment of opioid overdose. The agency's action date is October 31.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443211\" data-linked=\"FDA accepts Adamis Pharma&#39;s application for higher dose naloxone; shares up 2% premarket\" data-tweet=\"$ADMP - FDA accepts Adamis Pharma&#39;s application for higher dose naloxone; shares up 2% premarket https://seekingalpha.com/news/3443211-fda-accepts-adamis-pharmas-application-for-higher-dose-naloxone-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3443211-fda-accepts-adamis-pharmas-application-for-higher-dose-naloxone-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443207\" data-ts=\"1552655020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443207-morgan-stanley-transfers-feeder-fund-business-to-icapital-network\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley transfers feeder fund business to iCapital Network</a></h4><ul><li>Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>)<a href=\"https://seekingalpha.com/pr/17445348-icapital-network-enters-strategic-relationship-morgan-stanley-provide-alternative-investment\" target=\"_blank\"> will transfer</a> its alternative investments feeder fund business to iCapital Network, making iCapital the exclusive feeder fund service provider for Morgan Stanley's Wealth Management Alternative Investments Group.</li><li>The unit being transferred consists of ~115 investment vehicles across of range of investment strategies. Following the transaction, iCapital wills service ~$40B in private fund assets for more than 100,000 underlying accounts.</li><li>Terms of the deal weren't disclosed.</li><li>As part of the transaction, iCapital will offer positions to a group of Morgan Stanley employees who currently support alternative investment feeder fund oversight.</li><li>Morgan Stanley<font color=\"green\"> rises 0.3%</font>  in premarket trading.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3431572-morgan-stanleys-biggest-deal-since-financial-crisis\" target=\"_blank\">Morgan Stanley's biggest deal since financial crisis</a> (Feb. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443207\" data-linked=\"Morgan Stanley transfers feeder fund business to iCapital Network\" data-tweet=\"$MS - Morgan Stanley transfers feeder fund business to iCapital Network https://seekingalpha.com/news/3443207-morgan-stanley-transfers-feeder-fund-business-to-icapital-network?source=tweet\" data-url=\"https://seekingalpha.com/news/3443207-morgan-stanley-transfers-feeder-fund-business-to-icapital-network\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443196\" data-ts=\"1552654101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443196-bmo-likes-amgen-and-gilead-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMO likes Amgen and Gilead in premarket analyst action</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies, Inc.'>A</a>) initiated with Buy rating and $92 (14% upside) price target at UBS.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) initiated with Outperform rating and $228 (21% upside) at BMO.</li><li>Fluidigm (NASDAQ:<a href='https://seekingalpha.com/symbol/FLDM' title='Fluidigm Corporation'>FLDM</a>) initiated with Neutral rating and $14 (1% upside) price target at UBS. Shares up <font color=\"green\">5%</font> premarket.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) initiated with Outperform rating and $78 (20%) price target at BMO. Shares up <font color=\"green\">1%</font> premarket.</li><li>Magenta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGTA' title='Magenta Therapeutics, Inc.'>MGTA</a>) initiated with Outperform rating and $22 (73% upside) price target at Raymond James. Shares up <font color=\"green\">1%</font> premarket.</li><li>Urovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/UROV' title='Urovant Sciences Ltd.'>UROV</a>) initiated with Buy rating and $24 (75% upside) price target at SunTrust.</li><li>Xencor (NASDAQ:<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a>) initiated with Outperform rating and $40 (44% upside) price target at Raymond James.</li><li>QIAGEN (NYSE:<a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a>) initiated with Neutral rating and $42 (6% upside) price target at UBS.</li><li>BeiGene (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene, Ltd.'>BGNE</a>) initiated with Buy rating and $200 (48% upside) price target at BofA/Merrill Lynch.</li><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) resumed with Buy rating and $21 (104% upside) price target at Jefferies. Shares down <font color=\"red\">8%</font> premarket on withdrawal of Rolontis application in U.S.</li><li>RadNet (NASDAQ:<a href='https://seekingalpha.com/symbol/RDNT' title='RadNet, Inc.'>RDNT</a>) downgraded to Outperform (from Strong Buy) with a $17.50 (10% upside) price target at Raymond James.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443196\" data-linked=\"BMO likes Amgen and Gilead in premarket analyst action\" data-tweet=\"$A $AMGN $FLDM - BMO likes Amgen and Gilead in premarket analyst action https://seekingalpha.com/news/3443196-bmo-likes-amgen-and-gilead-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3443196-bmo-likes-amgen-and-gilead-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443195\" data-ts=\"1552653909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEMP\" target=\"_blank\">GEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443195-gemphire-therapeutics-beats-0_15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gemphire Therapeutics beats by $0.15</a></h4><ul><li>Gemphire Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics Inc.'>GEMP</a>): Q4 GAAP EPS of -$0.26 beats by $0.15.</li><li>Cash and cash equivalents  of $19M</li><li>Shares <font color=\"green\">+2.75%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17445478-gemphire-therapeutics-reports-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443195\" data-linked=\"Gemphire Therapeutics beats by $0.15\" data-tweet=\"$GEMP - Gemphire Therapeutics beats by $0.15 https://seekingalpha.com/news/3443195-gemphire-therapeutics-beats-0_15?source=tweet\" data-url=\"https://seekingalpha.com/news/3443195-gemphire-therapeutics-beats-0_15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443193\" data-ts=\"1552653582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIRK\" target=\"_blank\">KIRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443193-kirklandsminus-15-after-guidance-limps-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kirkland&#39;s -15% after guidance limps in</a></h4><ul> <li>Shares of Kirkland's (NASDAQ:<a href='https://seekingalpha.com/symbol/KIRK' title='Kirkland&#39;s, Inc.'>KIRK</a>) are <font color=\"red\">down 14.65%</font> after the retailer's full-year guidance arrives in below expectations.</li><li>Kirkland's expects revenue growth of 0% to +2% vs. +2.5% consensus and EPS of $0.15 to $0.30 vs. $0.40 consensus. The full year earnings projection assumes a tax rate of approximately 25% compared to a rate of 35% in FY18.</li>  <li>CEO update: \"While we made progress in key operational areas in 2018, we are disappointed with our overall performance and believe we need to accelerate the pace of change within the organization. We are taking meaningful steps to further transform the business to address ongoing changes in home décor retailing.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443113-kirklands-eps-line-misses-revenue\" target=\"_blank\">Kirkland's EPS in-line, misses on revenue</a> (March 15)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443193\" data-linked=\"Kirkland&#39;s -15% after guidance limps in\" data-tweet=\"$KIRK - Kirkland&#39;s -15% after guidance limps in https://seekingalpha.com/news/3443193-kirklandsminus-15-after-guidance-limps-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3443193-kirklandsminus-15-after-guidance-limps-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443191\" data-ts=\"1552653236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443191-soleno-up-44-premarket-on-continuation-of-dccr-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soleno up 44% premarket on continuation of DCCR study</a></h4><ul><li>Thinly traded nano cap Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) is up <font color=\"green\">44% </font>premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/17445121-soleno-therapeutics-announces-positive-outcome-planned-data-safety-monitoring-board-review\" target=\"_blank\">continuation </a>of its Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03440814?term=NCT03440814&amp;rank=1\" target=\"_blank\">DESTINY</a>, evaluating diazoxide choline controlled release &#40;DCCR&#41; in patients with Prader-Willi syndrome &#40;PWS&#41;, a Fast Track-designated indication in the U.S. and Orphan Drug indication in the U.S. and Europe. The independent Data Safety Monitoring Board recommended that the study continue without modification, further supporting DCCR's safety profile.</li><li>The primary endpoint is the change from baseline in hyperphagia score at week 13 (hyperphagia is an abnormally increased appetite that results in excessive eating and obesity).</li><li>The company adds that patients who have completed treatment in DESTINY continue to roll over into a nine-month open-label extension study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443191\" data-linked=\"Soleno up 44% premarket on continuation of DCCR study\" data-tweet=\"$SLNO - Soleno up 44% premarket on continuation of DCCR study https://seekingalpha.com/news/3443191-soleno-up-44-premarket-on-continuation-of-dccr-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3443191-soleno-up-44-premarket-on-continuation-of-dccr-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443189\" data-ts=\"1552652981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443189-snapplus-3-on-mobile-gaming-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +3% on mobile gaming report</a></h4><ul><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) will launch a new mobile gaming platform next month, according to Cheddar sources.</li><li>The games will come from external developers and details will be announced at a summit for game and development partners on April 4.</li><li>Snap shares are <font color=\"green\">up 3.2%</font> pre-market to $11.64.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443189\" data-linked=\"Snap +3% on mobile gaming report\" data-tweet=\"$SNAP - Snap +3% on mobile gaming report https://seekingalpha.com/news/3443189-snapplus-3-on-mobile-gaming-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3443189-snapplus-3-on-mobile-gaming-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443180\" data-ts=\"1552652448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443180-mgm-china-lands-crucial-macau-license-extension\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MGM China lands crucial Macau license extension</a></h4><ul> <li>MGM China (<a href='https://seekingalpha.com/symbol/MCHVF' title='MGM China Holdings Limited'>OTCPK:MCHVF</a>, <a href='https://seekingalpha.com/symbol/MCHVY' title='MGM China Holdings Limited'>OTCPK:MCHVY</a>) <font color=\"green\">gained 3.54%</font> in Hong Kong trading today after the company was awarded a two-year extension on its casino license by the Macau government.</li> <li>The extension means that MGM China will be part of the same bidding process as Sands China, Wynn Macau, Galaxy Entertainment and Melco Resorts &amp; Entertainment ahead of the June 2022 license expiration date.</li> <li>MGM Resorts (NYSE:<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a>) is <font color=\"green\">up 1.33%</font> in premarket trading in the U.S.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443180\" data-linked=\"MGM China lands crucial Macau license extension\" data-tweet=\"$MCHVF $MCHVY $MGM - MGM China lands crucial Macau license extension https://seekingalpha.com/news/3443180-mgm-china-lands-crucial-macau-license-extension?source=tweet\" data-url=\"https://seekingalpha.com/news/3443180-mgm-china-lands-crucial-macau-license-extension\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443179\" data-ts=\"1552652414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443179-achieve-life-sciences-up-83-on-advancement-of-cytisinicline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achieve Life Sciences up 83% on advancement of cytisinicline</a></h4><ul><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) is up <font color=\"green\">83%</font> premarket on robust volume following its <a href=\"https://seekingalpha.com/pr/17444885-achieve-reports-financial-results-year-end-2018-provides-cytisinicline-clinical-development\" target=\"_blank\">update </a>on smoking cessation med cytisinicline.</li><li>The Phase 2b <a href=\"https://clinicaltrials.gov/ct2/show/NCT03709823?lead=achieve+life+sciences&amp;phase=1&amp;rank=1\" target=\"_blank\">ORCA-1</a> study is now fully enrolled with 254 participants who will be randomized to receive either 1.5 mg, 3.0 mg of cytisinicline or placebo over 25 days. The primary endpoint is the reduction in the number of cigarettes smoked during the treatment period. Topline data should be available mid-year.</li><li>A previous study showed a <a href=\"https://seekingalpha.com/news/3436155-achieve-life-sciences-57-percent-premarket-positive-cytisinicline-data\" target=\"_blank\">significant effect</a> on smoking cessation.</li><li>The FDA has also signed off on including children under the age of 12 who smoke in the adolescent age group.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443179\" data-linked=\"Achieve Life Sciences up 83% on advancement of cytisinicline\" data-tweet=\"$ACHV - Achieve Life Sciences up 83% on advancement of cytisinicline https://seekingalpha.com/news/3443179-achieve-life-sciences-up-83-on-advancement-of-cytisinicline?source=tweet\" data-url=\"https://seekingalpha.com/news/3443179-achieve-life-sciences-up-83-on-advancement-of-cytisinicline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443178\" data-ts=\"1552652285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RKDA\" target=\"_blank\">RKDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443178-arcadia-biosciencesplus-26-on-receiving-fda-approval-for-sonova-gla-safflower-oil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcadia Biosciences +26% on receiving FDA approval for SONOVA GLA safflower oil</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17445306-arcadia-biosciences-receives-fda-approval-sonova-gla-safflower-oil-cat-food\" target=\"_blank\">granted</a> further approval to Arcadia Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences, Inc.'>RKDA</a>) SONOVA gamma linolenic acid &#40;GLA&#41; safflower oil as both safe and       nutritious for use in canine diets.</li>               <li>SONOVA is the only plant-based source of GLA approved for use as an       ingredient in US pet food.</li>     <li>Shares are up <font color=\"green\">26%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3443178\" data-linked=\"Arcadia Biosciences +26% on receiving FDA approval for SONOVA GLA safflower oil\" data-tweet=\"$RKDA - Arcadia Biosciences +26% on receiving FDA approval for SONOVA GLA safflower oil https://seekingalpha.com/news/3443178-arcadia-biosciencesplus-26-on-receiving-fda-approval-for-sonova-gla-safflower-oil?source=tweet\" data-url=\"https://seekingalpha.com/news/3443178-arcadia-biosciencesplus-26-on-receiving-fda-approval-for-sonova-gla-safflower-oil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443177\" data-ts=\"1552652196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRTX\" target=\"_blank\">TRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443177-tpg-re-finance-trust-prices-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TPG RE Finance Trust prices stock offering</a></h4><ul><li>TPG RE Finance Trust (NYSE:<a href='https://seekingalpha.com/symbol/TRTX' title='TPG RE Finance Trust, Inc.'>TRTX</a>) prices 6M common stock for total gross proceeds of $119.4M or $137.3M if underwriters exercise their full option to purchase additional 0.9M shares.</li><li>Closing date is March 19.</li><li>Net proceeds from the offering will be used to originate or acquire loans, for working capital and other general corporate purposes.</li><li>Shares <font color=\"red\">-3.5%</font> PM</li><li><a href=\"http://investors.tpgrefinance.com/file/Index?KeyFile=397130431\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443177\" data-linked=\"TPG RE Finance Trust prices stock offering\" data-tweet=\"$TRTX - TPG RE Finance Trust prices stock offering https://seekingalpha.com/news/3443177-tpg-re-finance-trust-prices-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3443177-tpg-re-finance-trust-prices-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443176\" data-ts=\"1552652177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443176-oracle-guides-weak-q4-gets-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle guides weak Q4, gets downgrade</a></h4><ul><li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) provides a downside Q4 outlook with the strengthening dollar posing an up to 3% headwind to total revenue with a -$0.03 impact on EPS.</li><li>Q4 EPS is expected from $1.05 to $1.09 or $1.08 to $1.12 in constant currency (consensus: $1.05). Revenue forecast is from $11.03B to $11.26B (consensus: $11.17B).</li><li>BMO downgrades Oracle from Outperform to Market Perform..</li><li>The firm \"modestly\" lowers its FY20 estimates. BMO thinks Oracle can sustain a roughly 2% CC revenue growth, but the firm is \"dubious\" that ORCL can improve revenue growth rates.</li><li>With the current valuation, BMO sees the risk-reward as balanced and steps to the sidelines.</li><li>Oracle shares are <font color=\"red\">down 3.5%</font> pre-market.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442955-oracle-reports-q3-beats\" target=\"_blank\">Oracle reports Q3 beats</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443176\" data-linked=\"Oracle guides weak Q4, gets downgrade\" data-tweet=\"$ORCL - Oracle guides weak Q4, gets downgrade https://seekingalpha.com/news/3443176-oracle-guides-weak-q4-gets-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3443176-oracle-guides-weak-q4-gets-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443175\" data-ts=\"1552651955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443175-selecta-biosciencesplus-13-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Biosciences +13% on Q4 results</a></h4><ul><li>Selecta Biosciences (<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) <a href=\"https://seekingalpha.com/pr/17445469-selecta-biosciences-announces-fourth-quarter-year-end-2018-financial-results-provides\" target=\"_blank\">Q4 results</a>: Revenues: $0.9M.</li><li>Net Loss: ($14.7M) (+24.6%); Loss Per Share: ($0.65) (+26.1%); Quick Assets: $37.4M (-61.3%).</li><li>Shares are up <font color=\"green\">13%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443171-selecta-biosciences-beats-0_05\" target=\"_blank\">Selecta Biosciences beats by $0.05</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443175\" data-linked=\"Selecta Biosciences +13% on Q4 results\" data-tweet=\"$SELB - Selecta Biosciences +13% on Q4 results https://seekingalpha.com/news/3443175-selecta-biosciencesplus-13-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443175-selecta-biosciencesplus-13-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443174\" data-ts=\"1552651909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443174-gunmaker-shares-rise-after-new-zealand-shootings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gunmaker shares rise after New Zealand shootings</a></h4><ul><li>American Outdoor (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>) and Sturm Ruger (NYSE:<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company, Inc.'>RGR</a>) are both <font color=\"green\">up 1%</font> premarket after 49 people were killed during mass shootings at two mosques in New Zealand.</li><li>At least 20 other people are being treated for gunshot wounds and are in serious condition.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443174\" data-linked=\"Gunmaker shares rise after New Zealand shootings\" data-tweet=\"$AOBC $RGR - Gunmaker shares rise after New Zealand shootings https://seekingalpha.com/news/3443174-gunmaker-shares-rise-after-new-zealand-shootings?source=tweet\" data-url=\"https://seekingalpha.com/news/3443174-gunmaker-shares-rise-after-new-zealand-shootings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443172\" data-ts=\"1552651680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIR\" target=\"_blank\">HAIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443172-restoration-roboticsplus-47-on-merger-venus-concept\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restoration Robotics +47% on merger with Venus Concept</a></h4><ul> <li>Restoration Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics, Inc.'>HAIR</a>) and Venus Concept Ltd. have entered into a definitive <a href=\"https://seekingalpha.com/pr/17445410-restoration-robotics-venus-concept-announce-merger-create-leading-global-medical-aesthetics\" target=\"_blank\">merger</a> agreement to combine the companies in an all-stock transaction. The merger is expected to close in Q3.</li>             <li>Under the terms of the transaction, Restoration Robotics and Venus Concept shareholders will own ~15% and 85% of the combined company, respectively.</li><li>EW Healthcare Partners has committed to lead a $21M equity investment, priced at $0.825/share, in the combined common.</li><li>Additionally, Fred Moll and InterWest Partners previously funded a $5M convertible note into Restoration Robotics which will convert into the combined company\u2019s common stock.</li>    <li>Concurrently, the Company anticipates effecting a reverse stock split. The Company expects to have ~283.2M shares outstanding (or ~18.9M shares outstanding after giving effect to an anticipated 1-for-15 reverse stock split).</li><li>HAIR shares are up <font color=\"green\">47%</font> premarket.</li>            </ul><div class=\"tiny-share-widget\" data-id=\"3443172\" data-linked=\"Restoration Robotics +47% on merger with Venus Concept\" data-tweet=\"$HAIR $VERO - Restoration Robotics +47% on merger with Venus Concept https://seekingalpha.com/news/3443172-restoration-roboticsplus-47-on-merger-venus-concept?source=tweet\" data-url=\"https://seekingalpha.com/news/3443172-restoration-roboticsplus-47-on-merger-venus-concept\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443171\" data-ts=\"1552651615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443171-selecta-biosciences-beats-0_05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Biosciences beats by $0.05</a></h4><ul><li>Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>): Q4 GAAP EPS of -$0.65 <span style=\"color:green\">beats by $0.05</span>.</li><li>Revenue of $0.9M (+4400.0% Y/Y)</li><li>Shares <font color=\"green\">+12.61%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17445469-selecta-biosciences-announces-fourth-quarter-year-end-2018-financial-results-provides\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443171\" data-linked=\"Selecta Biosciences beats by $0.05\" data-tweet=\"$SELB - Selecta Biosciences beats by $0.05 https://seekingalpha.com/news/3443171-selecta-biosciences-beats-0_05?source=tweet\" data-url=\"https://seekingalpha.com/news/3443171-selecta-biosciences-beats-0_05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443168\" data-ts=\"1552651518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KPTI\" target=\"_blank\">KPTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443168-karyopharm-up-17-premarket-on-extension-of-review-period-for-selinexor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Karyopharm up 17% premarket on extension of review period for selinexor</a></h4><ul><li>Karyopharm Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) is up <font color=\"green\">17%</font> premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17445029-karyopharm-announces-fda-extension-review-period-selinexor-new-drug-application\" target=\"_blank\">announcement </a>that the FDA has extended the review period 90 days for its marketing application seeking approval for selinexor, combined with dexamethasone, for the treatment of patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy and whose cancer has not responded to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.</li><li>The new action date is July 6.</li><li>On February 26, an FDA advisory committee <a href=\"https://seekingalpha.com/news/3437490-fda-advisory-committee-delays-vote-karyopharms-selinexor\" target=\"_blank\">voted to delay</a> its vote on the application until it reviewed the results from the Phase 3 BOSTON study.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443168\" data-linked=\"Karyopharm up 17% premarket on extension of review period for selinexor\" data-tweet=\"$KPTI - Karyopharm up 17% premarket on extension of review period for selinexor https://seekingalpha.com/news/3443168-karyopharm-up-17-premarket-on-extension-of-review-period-for-selinexor?source=tweet\" data-url=\"https://seekingalpha.com/news/3443168-karyopharm-up-17-premarket-on-extension-of-review-period-for-selinexor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443157\" data-ts=\"1552651047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPLO\" target=\"_blank\">DPLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443157-diplomat-pharmacy-down-19-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diplomat Pharmacy down 19% on Q4 results</a></h4><ul><li>Diplomat Pharmacy (<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) <a href=\"https://seekingalpha.com/pr/17445429-diplomat-announces-4th-quarter-2018-year-end-financial-results-provides-revised-2019-guidance\" target=\"_blank\">Q4 results</a>: Revenues: $1,360.6M (+17.8%).</li><li>Net Loss: ($298M); Loss Per Share: ($4.00); Quick Assets: $9.5M (-88.7%); CF Ops: $35M (-74.1%).</li><li><strong>2019 Guidance</strong>: $4.7B - 5B, versus the previous range of $5.6B - 5.8B; Net Loss: ($37M - 26M); Loss Per Share: ($0.50 - 0.34); Adjusted EBITDA: $110M - 116M.</li><li>Shares are down <font color=\"red\">19%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443141-diplomat-pharmacy-eps-4_00\" target=\"_blank\">Diplomat Pharmacy EPS of -$4.00</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443157\" data-linked=\"Diplomat Pharmacy down 19% on Q4 results\" data-tweet=\"$DPLO - Diplomat Pharmacy down 19% on Q4 results https://seekingalpha.com/news/3443157-diplomat-pharmacy-down-19-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443157-diplomat-pharmacy-down-19-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443155\" data-ts=\"1552650906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMED\" target=\"_blank\">OMED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443155-oncomed-declares-one-time-contractual-right-dividend-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoMed declares one-time contractual right dividend; shares up 7% premarket</a></h4><ul><li>The board of OncoMed Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/OMED' title='OncoMed Pharmaceuticals, Inc.'>OMED</a>) has <a href=\"https://seekingalpha.com/pr/17445397-oncomed-pharmaceuticals-declares-special-dividend-contingent-value-rights\" target=\"_blank\">declared </a>a one-time special dividend to stockholders in the form of a contractual right to receive cash payments related to Celgene's (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) option on etigilimab.</li><li>OMED shareholders of record on April 5 will be eligible to receive the money if a certain regulatory or sales milestone is achieved or if CELG pays royalties to OMED or its affiliates.</li><li>OMED is up <font color=\"green\">7%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443155\" data-linked=\"OncoMed declares one-time contractual right dividend; shares up 7% premarket\" data-tweet=\"$OMED $CELG - OncoMed declares one-time contractual right dividend; shares up 7% premarket https://seekingalpha.com/news/3443155-oncomed-declares-one-time-contractual-right-dividend-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3443155-oncomed-declares-one-time-contractual-right-dividend-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443150\" data-ts=\"1552650386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIR\" target=\"_blank\">HAIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443150-restoration-robotics-q4-top-line-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restoration Robotics Q4 top line up 14%</a></h4><ul><li>Restoration Robotics (<a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics, Inc.'>HAIR</a>) <a href=\"https://seekingalpha.com/pr/17445412-restoration-robotics-reports-financial-results-fourth-quarter-full-year-2018\" target=\"_blank\">Q4 results</a>: Revenues: $6.7M (+13.6%).</li><li>Net Loss: ($8M); Loss Per Share: ($0.20); Quick Assets: $16.1M (-31.5%).</li><li>Shares are up <font color=\"green\">31%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443125-restoration-robotics-misses-0_03-beats-revenue\" target=\"_blank\">Restoration Robotics misses by $0.03, beats on revenue</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443150\" data-linked=\"Restoration Robotics Q4 top line up 14%\" data-tweet=\"$HAIR $VERO - Restoration Robotics Q4 top line up 14% https://seekingalpha.com/news/3443150-restoration-robotics-q4-top-line-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3443150-restoration-robotics-q4-top-line-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443144\" data-ts=\"1552649782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443144-keybanc-ups-amazon-on-accelerating-profitability\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc ups Amazon on &quot;accelerating profitability&quot;</a></h4><ul><li>KeyBanc upgrades Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) from Sector Weight to Overweight with a $2,100 price target, implying a nearly 25% upside.</li><li>The firm says Amazon is \"pivoting to a company with accelerating profitability\" as it takes a \"number of operational moves\" to improve core retail profits, which could drive mid-term earnings above consensus.</li><li>Example operational moves: Shuttering the <a href=\"https://seekingalpha.com/news/3440409-amazon-closing-u-s-pop-ups-wsj\" target=\"_blank\">pop-up kiosks</a> and pursuing a <a href=\"https://seekingalpha.com/news/3439204-amazon-plans-new-grocery-chain-report\" target=\"_blank\">mid-market grocery</a> business.</li><li>KeyBanc thinks AWS and advertising could boost margins by $100B and significantly expand margins.</li><li>Amazon shares are <font color=\"green\">up 1.3%</font> pre-market to $1,707.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443144\" data-linked=\"KeyBanc ups Amazon on &quot;accelerating profitability&quot;\" data-tweet=\"$AMZN - KeyBanc ups Amazon on &quot;accelerating profitability&quot; https://seekingalpha.com/news/3443144-keybanc-ups-amazon-on-accelerating-profitability?source=tweet\" data-url=\"https://seekingalpha.com/news/3443144-keybanc-ups-amazon-on-accelerating-profitability\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443140\" data-ts=\"1552649463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTS\" target=\"_blank\">LTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443140-ladenburg-thalmannplus-2_1-after-posting-q4-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ladenburg Thalmann +2.1% after posting Q4 profit</a></h4><ul><li>Ladenburg Thalmann Financial Services (NYSEMKT:<a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a>) rises 2.1% in premarket trading after <a href=\"https://seekingalpha.com/pr/17445363-ladenburg-reports-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\"> Q4 net income</a>, excluding the effect of adopting ASC 606, of $0.5M, or break-even on a per share basis, compares with a loss of $1.8M, or 1 cent per share, in the year-ago quarter.</li><li>Q4 GAAP EPS of 1 cent came in-line with the consensus estimate.</li><li>Q4 adjusted EBITDA of $29.1M jumped 56% from $18.7M in the year-ago period.</li><li>Q4 revenue, excluding ASC 606, of $393.5M rose 14% from $344.0M in the year-ago period.</li><li>Client assets under management of $166.4B at Jan. 31, 2019 increases from $158.6B at Dec. 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443136-ladenburg-thalmann-financial-eps-revenue-line\" target=\"_blank\">Ladenburg Thalmann Financial EPS and revenue in-line</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443140\" data-linked=\"Ladenburg Thalmann +2.1% after posting Q4 profit\" data-tweet=\"$LTS - Ladenburg Thalmann +2.1% after posting Q4 profit https://seekingalpha.com/news/3443140-ladenburg-thalmannplus-2_1-after-posting-q4-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3443140-ladenburg-thalmannplus-2_1-after-posting-q4-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443137\" data-ts=\"1552649251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443137-spectrum-withdraws-u-s-marketing-application-for-rolontis-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum withdraws U.S. marketing application for Rolontis; shares down 8% premarket</a></h4><ul><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) is down <font color=\"red\">8%</font> premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17445368-spectrum-pharmaceuticals-provides-bla-filing-update-rolontis-eflapegrastim\" target=\"_blank\">withdrawal </a>of its U.S. marketing application seeking approval for ROLONTIS (eflapegrastim) for the management of chemo-induced neutropenia in patients undergoing myelosuppressive chemo.</li><li>The company says it needs more time to provide additional manufacturing-related information to the FDA, required before the end of the agency's 60-day review period on March 29.</li><li>It plans to refile the application as soon as possible.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443137\" data-linked=\"Spectrum withdraws U.S. marketing application for Rolontis; shares down 8% premarket\" data-tweet=\"$SPPI - Spectrum withdraws U.S. marketing application for Rolontis; shares down 8% premarket https://seekingalpha.com/news/3443137-spectrum-withdraws-u-s-marketing-application-for-rolontis-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3443137-spectrum-withdraws-u-s-marketing-application-for-rolontis-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443136\" data-ts=\"1552649108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTS\" target=\"_blank\">LTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443136-ladenburg-thalmann-financial-eps-and-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ladenburg Thalmann Financial EPS and revenue in-line</a></h4><ul><li>Ladenburg Thalmann Financial (NYSEMKT:<a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a>): Q4 GAAP EPS of $0.01 in-line.</li><li>Revenue of $355.12M (+3.2% Y/Y) in-line.</li><li>Shares <font color=\"green\">+2.12%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17445363-ladenburg-reports-fourth-quarter-fiscal-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443136\" data-linked=\"Ladenburg Thalmann Financial EPS and revenue in-line\" data-tweet=\"$LTS - Ladenburg Thalmann Financial EPS and revenue in-line https://seekingalpha.com/news/3443136-ladenburg-thalmann-financial-eps-and-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3443136-ladenburg-thalmann-financial-eps-and-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443130\" data-ts=\"1552648582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOS\" target=\"_blank\">BIOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443130-bioscrip-and-option-care-enterprises-to-merge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioScrip and Option Care Enterprises to merge</a></h4><ul><li>Biocrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) and home infusion services provider <a href=\"https://optioncare.com/\" target=\"_blank\">Option Care Enterprises</a> have agreed to <a href=\"http://www.globenewswire.com/news-release/2019/03/15/1755187/0/en/Home-and-Alternate-Site-Infusion-Therapy-Providers-BioScrip-and-Option-Care-to-Merge.html\" target=\"_blank\">merge </a>in an all-stock transaction. Under the terms of the deal, BIOS will issue new shares to Option Care's shareholder, owned by funds affiliated with Madison Dearborn Partners, LLC and Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>). Both will own 80% of the combined company with Bioscrip owning 20%.</li><li>Option Care CEO John Rademacher will lead the new company while CFO Mike Shapiro will head finance. Bioscrip President &amp; CEO Daniel Greenleaf will serve as a special advisor to the board.</li><li>BIOS will resume trading at 7:30 am ET.</li><li>The companies will host a conference call this morning at 9:00 am ET to discuss the tie-up.</li><li><strong>Update</strong>: BIOS is up <font color=\"green\">28%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443130\" data-linked=\"BioScrip and Option Care Enterprises to merge\" data-tweet=\"$BIOS $WBA - BioScrip and Option Care Enterprises to merge https://seekingalpha.com/news/3443130-bioscrip-and-option-care-enterprises-to-merge?source=tweet\" data-url=\"https://seekingalpha.com/news/3443130-bioscrip-and-option-care-enterprises-to-merge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443127\" data-ts=\"1552647898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCA\" target=\"_blank\">MDCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443127-mdc-partners-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDC Partners misses on revenue</a></h4><ul><li>MDC Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCA' title='MDC Partners Inc.'>MDCA</a>): Q4 GAAP EPS of -$1.46.</li><li>Revenue of $393.66M (-2.3% Y/Y) <font color=\"red\">misses by $0.44M</font>.</li><li>Shares <font color=\"green\">+33%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17445402-mdc-partners-inc-reports-results-three-twelve-months-ended-december-31-2018\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443127\" data-linked=\"MDC Partners misses on revenue\" data-tweet=\"$MDCA - MDC Partners misses on revenue https://seekingalpha.com/news/3443127-mdc-partners-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443127-mdc-partners-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443118\" data-ts=\"1552647591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOS\" target=\"_blank\">BIOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443118-bioscrip-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioScrip halted pending news</a></h4><ul><li>Nasdaq has suspended trading in BioScrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443118\" data-linked=\"BioScrip halted pending news\" data-tweet=\"$BIOS - BioScrip halted pending news https://seekingalpha.com/news/3443118-bioscrip-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3443118-bioscrip-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443115\" data-ts=\"1552647018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRN\" target=\"_blank\">CTRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443115-citi-trends-beats-0_03-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi Trends beats by $0.03, misses on revenue</a></h4><ul><li>Citi Trends (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a>): Q4 GAAP EPS of $0.59 <span style=\"color:green\">beats by $0.03</span>.</li><li>Revenue of $201.16M (-5.2% Y/Y) <font color=\"red\">misses by $13.84M</font>.</li><li>Shares <font color=\"green\">+2.59%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17445354-citi-trends-announces-fourth-quarter-and-full-year-2018-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443115\" data-linked=\"Citi Trends beats by $0.03, misses on revenue\" data-tweet=\"$CTRN - Citi Trends beats by $0.03, misses on revenue https://seekingalpha.com/news/3443115-citi-trends-beats-0_03-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443115-citi-trends-beats-0_03-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}